26
Mar, 2019
Cancer risk in families
If you have family members with cancer, you may wonder if you are at risk of developing it too (if it “runs in the family”). Sometimes a gene mutation that can cause cancer is passed on to you by…
READ MORE
Leading the world in
early cancer detection research
Our innovative cancer screening
studies mean better outcomes for patients
Innovation in cancer research
and development
We are changing the face of cancer detection
and treatment using the latest
advancements in Metabolomics
Non-invasive and affordable early
cancer
screening and monitoring
solution
90% of cancers are curable if caught early
Your Health is Our Focus!
BIOMARK’S MISSION
To provide universal access to a new paradigm in cancer diagnostics using metabolomics.
WHAT IS A BIOMARKER?
According to the National Cancer Institute a biomarker is “a biological molecule found in blood, other body fluids or tissues that is a sign of a normal or abnormal process or of a condition or disease” (NCI) such as cancer.
Biomarkers typically differentiate an affected patient from a person without the disease. There is tremendous variety of biomarkers which can include:
- proteins (e.g. an enzyme or receptor)
- nucleic acids (e.g. a microRNA or other non-coding RNA)
- antibodies
- and peptides among other categories
A biomarker can also be a collection of alterations such as gene expression, proteomic, and metabolomic signatures.
Biomarkers can be detected in the circulation (whole blood, serum, or plasma) or excretions or secretions (stool, urine, sputum, or nipple discharge) and thus easily assessed non-invasively and serially. Biomarkers can also be tissue-derived and require either biopsy or special imaging for evaluation.
Sign up to learn about new research and developments from BioMark
POTENTIAL CLINICAL USES OF CANCER BIOMARKERS
Biomarkers have many potential applications in oncology including:
- Estimating risk of cancer
- Screening for occult primary cancers
- Distinguishing benign from malignant findings or one type of malignancy from another
- Monitoring status of the disease either to detect recurrence or determine response or progression to therapy
- Personalizing a treatment program especially for immunotherapy applications
- Help in assessing pseudo progression with imaging modalities
LATEST NEWS
26
Mar, 2019
About Glioblastoma (GBM)
Overview Tumour Group: Gliomas WHO Grade: Grade IV Prevalence/Incidence: The incidence of glioblastoma multiforme (GBM) is 2 to 3 per 100,000 people in the United States and Europe. GBM accounts for 12 to 15% of all intracranial tumours and 50 to 60 per cent of astrocytic tumours. GBMs increase in frequency with age, and affect more men than women. Typical Age Range: GBMs may manifest at any age, but mostly…
READ MORENEWS RELEASES
BioMark Contributes Additional Scientific Publication
March 14, 2019
Vancouver, British Columbia – (March 14th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Use of amantadine as substrate for SSAT-1 activity as a reliable clinical diagnostic assay for breast and lung cancer” has been published in the peer-reviewed journal Future Science OA. Rashid Ahmed, President and CEO, says, “This is our follow up publication and we would like to acknowledge the contributions made by a dedicated team of clinicians, scientists and researchers. This publication provides further scientific […]
READ MORE
STOCK QUOTE
BIOMARK AWARDS, GRANTS, RECOGNITIONS
BioMark has been funded by various government agencies including NRC IRAP, NRC Engage, Genome BC, Government of Manitoba and DFAIT Canada for various projects with active collaboration at University of British Columbia, University of Manitoba, University of Victoria, University of Waterloo, and University of Alberta since 2006. New research applications to Genome Canada and Genome BC Strategic Innovation Program were submitted in 2017 reviewed by peer groups. Now BioMark is collaborating with Bio banks across Canada to expand our metabolomics study.